- Home
- HLP vs RPTX Comparison
HLP vs RPTX Comparison
Compare HLP & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- RPTX
- Stock Information
- Founded
- HLP 2021
- RPTX 2016
- Country
- HLP China
- RPTX Canada
- Employees
- HLP N/A
- RPTX N/A
- Industry
- HLP Industrial Machinery/Components
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- HLP Industrials
- RPTX Health Care
- Exchange
- HLP Nasdaq
- RPTX Nasdaq
- Market Cap
- HLP 65.3M
- RPTX 64.8M
- IPO Year
- HLP 2023
- RPTX 2020
- Fundamental
- Price
- HLP $0.65
- RPTX $1.54
- Analyst Decision
- HLP
- RPTX Strong Buy
- Analyst Count
- HLP 0
- RPTX 3
- Target Price
- HLP N/A
- RPTX $4.50
- AVG Volume (30 Days)
- HLP 79.5K
- RPTX 707.7K
- Earning Date
- HLP 09-18-2025
- RPTX 08-12-2025
- Dividend Yield
- HLP N/A
- RPTX N/A
- EPS Growth
- HLP N/A
- RPTX N/A
- EPS
- HLP N/A
- RPTX N/A
- Revenue
- HLP $14,105,620.00
- RPTX $1,073,000.00
- Revenue This Year
- HLP N/A
- RPTX N/A
- Revenue Next Year
- HLP N/A
- RPTX N/A
- P/E Ratio
- HLP N/A
- RPTX N/A
- Revenue Growth
- HLP N/A
- RPTX N/A
- 52 Week Low
- HLP $0.61
- RPTX $0.89
- 52 Week High
- HLP $2.13
- RPTX $4.07
- Technical
- Relative Strength Index (RSI)
- HLP 41.42
- RPTX 55.09
- Support Level
- HLP $0.62
- RPTX $1.48
- Resistance Level
- HLP $0.71
- RPTX $1.62
- Average True Range (ATR)
- HLP 0.05
- RPTX 0.05
- MACD
- HLP 0.01
- RPTX -0.01
- Stochastic Oscillator
- HLP 38.14
- RPTX 42.86
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.